Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.48 |
| ▸ | MAX | P61244 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 2/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.44 |
| ▸ | NAT1 | P18440 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804713 | 0.82 | PIM1 (0.47) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL18163760 | 0.82 | MYC (0.53) | MYCMAXNPC1RAB9AHPGD | |
| SCHEMBL679543 | 0.77 | PIM1 (0.46) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL679542 | 0.77 | PIM1 (0.46) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL679544 | 0.77 | PIM1 (0.46) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL678089 | 0.76 | PIM1 (0.45) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL679788 | 0.76 | PIM1 (0.45) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL678088 | 0.76 | PIM1 (0.45) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL679773 | 0.76 | PIM1 (0.45) | NPC1RAB9AHPGDPDE4BTDP1 | |
| SCHEMBL679775 | 0.76 | PIM1 (0.45) | NPC1RAB9AHPGDPDE4BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2023-02-21 | — | — | US | disclosed |
| EP-4029859-A1 | 2-OXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM THERAPEUTICS, S.A. (PT) | 2022-07-20 | — | — | EP | disclosed |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | BSIM THERAPEUTICS, S.A. (PT) | 2021-09-14 | — | — | US | disclosed |
| CN-107008497-B | A kind of preparation method and its non-imidazole base acidic ionic liquid catalysts of preparation of 5- aryl methylene Rhodanine derivates | 马鞍山市泰博化工科技有限公司 | 2019-05-17 | — | — | CN | disclosed |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 - Biomolecular Simulations Lda. (PT) | 2019-03-28 | — | — | US | disclosed |
| EP-3221299-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 Biomolecular Simulations Lda. (PT) | 2017-09-27 | — | — | EP | disclosed |
| CN-107008497-A | The preparation methods of 5 aryl methylene Rhodanine derivates a kind of and its prepare with non-imidazole base acidic ionic liquid catalysts | 马鞍山市泰博化工科技有限公司 | 2017-08-04 | — | — | CN | disclosed |
| US-20170165361-A1 | TREATMENT OF LYSOSOMAL DISORDERS (ANTI-TNF THERAPY) | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-06-15 | — | — | US | disclosed |
| US-9551036-B2 | Metabolic gene mesenchymal signatures and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016080853-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | BSIM2 – BIOMOLECULAR SIMULATIONS LDA (PT) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016005748-A1 | TREATMENT OF LYSOSOMAL DISORDERS (ANTI-TNF THERAPY) | ISIS INNOVATION LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-20140357693-A1 | METABOLIC GENE MESENCHYMAL SIGNATURES AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-12-04 | — | — | US | disclosed |
| US-20090204336-A1 | PDZ-Domain Modulators | FORSCHUNGSVERBUND BERLIN E. V. (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-1893199-A2 | PDZ-DOMAIN MODULATORS | Forschungsverbund Berlin e.V. (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006119736-A2 | PDZ-DOMAIN MODULATORS | COMBINATURE BIOPHARM AG (DE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | MYC 3638/4885MAX 1007/4885NPC1 920/4885 |
| US-20190092737-A1 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF | TTR, TTPA, MTPN | MYC 3638/4885MAX 1007/4885NPC1 920/4885 |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | TTR, TTPA, MTPN | MYC 3023/4885MAX 525/4885NPC1 865/4885 |
| US-20090204336-A1 | PDZ-Domain Modulators | PDLIM5, DVL1, PSD | MYC 3008/4885MAX 2970/4885NPC1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.